Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCB-2020S
NCT05228314Phase 1Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCB-2020S in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Number of participants with local and systemic adverse events, Number of participants with unsolicited adverse events and 2 more. Started May 2022; status: completed.
02
Drugs
SCB-2020S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05228314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228314.